Bioanalytical Method List
Anapharm Bioanalytics offers an extensive list of validated analytical methods to support bioequivalence, drug-drug interaction and other types of studies. If you are unable to find the assay you need or require the development of a proprietary method, please contact us; we shall be glad to assist you.
Find your method here:
Alternatively, you will find the complete list of assays listed alphabetically below:
List of bioanalytical methods
| Compound | Platform | Calibration Range | Biological Matrix |
|---|---|---|---|
| Abiraterone | LC/MS/MS | 0.2-100 ng/mL | Human EDTA Plasma |
| Abiraterone | LC/MS/MS | 0.5-200 ng/mL | Human EDTA Plasma |
| Abiraterone | LC/MS/MS | 2-1250 ng/mL | Human EDTA Plasma |
| Aceclofenac | LC/MS/MS | 15-15000 ng/mL | Human EDTA Plasma |
| Acetazolamide | LC/MS/MS | 50-20000 ng/mL | Human EDTA Plasma |
| Acetylsalicylic Acid; Salicylic Acid | LC/MS/MS | 10-5000 ng/mL; 80-20000 ng/mL | Human EDTA Plasma |
| Acetylsalicylic Acid; Salicylic Acid | LC/MS/MS | 10-6000 ng/mL; 100-30000 ng/mL | Human EDTA Plasma |
| Acetylsalicylic Acid; Salicylic Acid | LC/MS/MS | 10-2500 ng/mL; 100-10000 ng/mL | Human EDTA Plasma |
| Acetylsalicylic Acid; Salicylic Acid | LC/MS/MS | 20-12000 ng/mL; 200-60000 ng/mL | Human EDTA Plasma |
| Acyclovir | LC/MS/MS | 20-1600 pg/mL | Human EDTA Plasma |
| Acyclovir | LC/MS/MS | 10-4000 ng/mL | Human EDTA Plasma |
| Acyclovir | LC/MS/MS | 2-1000 ng/mL | Human EDTA Plasma |
| Adefovir | LC/MS/MS | 0.1-50 ng/mL | Human EDTA Plasma |
| Agomelatine | LC/MS/MS | 50-10000 pg/mL | Human EDTA Plasma |
| Agomelatine | LC/MS/MS | 50-20000 pg/mL | Human EDTA Plasma |
| Alendronic Acid (Alendronate) | LC/MS/MS | 0.1-100 ng/mL | Human EDTA Plasma |
| Almotriptan | LC/MS/MS | 0.5-100 ng/mL | Human EDTA Plasma |
| Alprazolam | LC/MS/MS | 0.2-40 ng/mL | Human EDTA Plasma |
| Amlodipine | LC/MS/MS | 50-15000 pg/mL | Human EDTA Plasma |
| Amlodipine | LC/MS/MS | 50-7500 pg/mL | Human EDTA Plasma |
| Amlodipine | LC/MS/MS | 50-5000 pg/mL | Human EDTA Plasma |
| Amoxicillin | LC/MS/MS | 200-20000 ng/mL | Human EDTA Plasma |
| Amoxicillin | LC/MS/MS | 50-10000 ng/mL | Human EDTA Plasma |
| Anagrelide | LC/MS/MS | 50-15000 pg/mL | Human EDTA Plasma |
| Anagrelide | LC/MS/MS | 50-10000 pg/mL | Human EDTA Plasma |
| Anastrozole | LC/MS/MS | 0.1-20 ng/mL | Human EDTA Plasma |
| Anidulafungin | UPLC/MS/MS | 50-10000 ng/mL | Human EDTA Plasma |
| Anti-FIIa | Chromogenic Assay | 0.035-0.5 IU/mL | Human CTAD Plasma |
| Anti-FXa | Chromogenic Assay | 0.1-1.00 IU/mL | Human CTAD Plasma |
| Apixaban | LC/MS/MS | 1–300 ng/mL | Human EDTA Plasma |
| Apixaban | LC/MS/MS | 0.5–150 ng/mL | Human EDTA Plasma |
| Apomorphine | UPLC/MS/MS | 50-100000 pg/mL | Human EDTA Plasma |
| Apomorphine | UPLC/MS/MS | 10-2000 ng/mL | Rat Plasma |
| Aprepitant | LC/MS/MS | 20-2000 ng/mL | Human EDTA Plasma |
| Aprepitant | UPLC/MS/MS | 5-2000 ng/mL | Beagle Dog EDTA Plasma |
| Aripiprazole | LC/MS/MS | 0.5-100 ng/mL | Human EDTA Plasma |
| Aripiprazole | LC/MS/MS | 0.5-50 ng/mL | Human EDTA Plasma |
| Asenapine | UPLC/MS/MS | 50-15000 pg/mL | Human EDTA Plasma |
| Atazavanir | LC/MS/MS | 2-2000 ng/mL | Human EDTA Plasma |
| Atenolol | LC/MS | 5-1000 ng/mL | Human Sodium Heparinized Plasma |
| Atomoxetine | UPLC/MS/MS | 2-1000 ng/mL | Human EDTA Plasma |
| Atomoxetine | LC/MS/MS | 2-500 ng/mL | Human EDTA plasma |
| Atorvastatin | LC/MS/MS | 0.25-50 ng/mL | Human EDTA Plasma |
| Atorvastatin; o- OH- Atorvastatin; p- OH- Atorvastatin | LC/MS/MS | 50-10000 pg/mL; 50-10000 pg/mL; 50-1000 pg/mL | Human EDTA Plasma |
| Atorvastatin; o- OH- Atorvastatin; p- OH- Atorvastatin | LC/MS/MS | 50-7500 pg/mL; 50-2500 pg/mL; 50-1000 pg/mL | Human EDTA Plasma |
| Atorvastatin; o- OH- Atorvastatin; p- OH- Atorvastatin | UPLC/MS/MS | 50-75000 pg/mL; 50-75000 pg/mL; 50-5000 pg/mL | Human EDTA Plasma |
| Atorvastatin; o- OH- Atorvastatin; p- OH- Atorvastatin | LC/MS/MS | 0.25-75 ng/mL; 0.25-75 ng/mL; 50-5000 pg/mL | Human EDTA Plasma |
| Azithromycin | LC/MS/MS | 5-1000 ng/mL | Human EDTA Plasma |
| Azithromycin | LC/MS/MS | 5-1000 ng/mL | Human EDTA Plasma |
| Barnidipine | LC/MS/MS | 20-2000 pg/mL | Human EDTA Plasma |
| Benznidazole | LC/MS/MS | 50-3000 ng/mL | Human EDTA Plasma |
| Betahistine metabolite (2-pyridylacetic acid ) | LC/MS/MS | 2-800 ng/mL | Human EDTA Plasma |
| Betaxolol | LC/MS/MS | 0.5-50 ng/mL | Human EDTA Plasma |
| Bicalutamide | LC/MS/MS | 10-1000 ng/mL | Human EDTA Plasma |
| Bicalutamide (R-(-) Bicalutamide; S-(+) Bicalutamide) | LC/MS/MS | 1-1000ng/mL; 0.5-100 ng/mL | Human EDTA Plasma |
| Bicalutamide (R-(-) Bicalutamide; S-(+) Bicalutamide) | LC/MS/MS | 5-1000 ng/mL; 5-200 ng/mL | Human EDTA Plasma |
| Bicalutamide (R-(-)Bicalutamide ; S-(+) Bicalutamide) | LC/MS/MS | 1-2000 ng/mL; 0.5-200 ng/mL | Human EDTA Plasma |
| Bilastine | UPLC/MS/MS | 1-400 ng/mL | Human Sodium Heparinized Plasma |
| Bisoprolol | LC/MS/MS | 0.5-100 ng/mL | Human EDTA Plasma |
| Bisoprolol | LC/MS/MS | 0.5-50 ng/mL | Human EDTA Plasma |
| Bosentan | LC/MS/MS | 5-3000 ng/mL | Human EDTA Plasma |
| Brinzolamide | LC/MS/MS | 50-10000 ng/mL | Human Whole Blood |
| Budesonide | LC/MS/MS | 5-1000 pg/mL | Human EDTA Plasma |
| Buprenorphine | LC/MS/MS | 3-400 pg/mL | Human EDTA Plasma |
| Buprenorphine; Norbuprenorphine | LC/MS/MS | 5-400 pg/mL; 10-400 pg/mL | Human EDTA Plasma |
| Bupropion; Hydroxybupropion | LC/MS/MS | 1-200 ng/mL; 1-400 ng/mL | Human EDTA Plasma |
| Bupropion; hydroxybupropion; erythrohydroxybupropion; threohydroxybupropion | LC/MS/MS | 1-500 ng/mL; 3-1500 ng/mL; 1-100 ng/mL; 1-500 ng/mL | Human EDTA Plasma |
| Caffeine | LC/MS/MS | 20-2000 ng/mL | Human EDTA Plasma |
| Canagliflozin | UPLC/MS/MS | 10-4000 ng/mL | Human EDTA Plasma |
| Candesartan | LC/MS/MS | 0.5-75 ng/mL | Human EDTA Plasma |
| Candesartan | LC/MS/MS | 0.5-125 ng/mL | Human EDTA Plasma |
| Candesartan | LC/MS/MS | 1-250 ng/mL | Human EDTA Plasma |
| Candesartan | LC/MS/MS | 1-500 ng/mL | Human EDTA Plasma |
| Cannabidiol; 7‑hydroxycannabidiol; 7-Nor-7-carboxycannabidiol | UPLC/MS/MS | 100 ‑ 10000 pg/mL; 100 ‑ 10000 pg/mL; 1000 ‑ 100000 pg/mL | Human EDTA Plasma |
| Capecitabine | LC/MS/MS | 2-1000 ng/mL | Human EDTA Plasma |
| Capecitabine; 5 Fluorouracil (5-FU) | LC/MS/MS | 10-5000 ng/mL; 2-1000 ng/mL | Human EDTA Plasma |
| Capecitabine; 5´-DFCR | LC/MS/MS | 10-5000 ng/mL | Human EDTA Plasma |
| Carbidopa ; Levodopa | LC/MS/MS | 5-250 ng/mL; 10-2500 ng/mL | Human EDTA Plasma |
| Carbidopa ; Levodopa | LC/MS/MS | 2-75 ng/mL; 10-750 ng/mL | Human EDTA Plasma |
| Carbidopa ; Levodopa | LC/MS/MS | 5-300 ng/mL; 10-2500 ng/mL | Human EDTA Plasma |
| Carbidopa ; Levodopa | LC/MS/MS | 2-100 ng/mL; 10-750 ng/mL | Human EDTA Plasma |
| Carbocisteine | LC/MS/MS | 30-6000 ng/mL | Human EDTA Plasma |
| Carisoprodol; Meprobamate | LC/MS/MS | 10-8000 ng/mL ; 10-8000 ng/mL | Human EDTA Plasma |
| Cefaclor | LC/MS/MS | 0.2-40 ng/mL | Human EDTA Plasma |
| Cefaclor | LC/MS/MS | 50-25000 ng/mL | Human EDTA Plasma |
| Cefadroxil | LC/MS/MS | 0.2-40 μg/mL | Human EDTA Plasma |
| Cefadroxil | LC/MS/MS | 0.2-15 μg/mL | Human EDTA Plasma |
| Cefditoren | LC/MS/MS | 30-6000 ng/mL | Human EDTA Plasma |
| Cefixime | LC/MS/MS | 2-10000 ng/mL | Human EDTA Plasma |
| Cefpodoxime | LC/MS/MS | 20-5000 ng/mL | Human EDTA Plasma |
| Celecoxib | LC/MS | 10-2000 ng/mL | Human Lithium Heparinized Plasma |
| Cetirizine | LC/MS | 2-200 ng/mL | Human EDTA Plasma |
| Chlorphenamine (refer to Chlorpheniramine) | |||
| Chlorpheniramine | LC/MS/MS | 0.2-25 ng/mL | Human EDTA Plasma |
| Chlorpheniramine (S-(+)-clorpheniramine; R-(-)-Chlorpheniramine) | LC/MS/MS | 50-10000 pg/mL; 50-5000 pg/mL | Human EDTA Plasma |
| Chlorthalidone | LC/MS/MS | 2-1000 ng/mL | Human EDTA Plasma |
| Chlorthalidone | LC/MS/MS | 10-5000 ng/mL | Human Whole Blood |
| Cholecalciferol (Vitamin D3) | LC/MS/MS | 0.15-15 ng/mL | Human EDTA Plasma |
| Cholecalciferol (Vitamin D3) | LC/MS/MS | 0.25-25 ng/mL | Human EDTA Plasma |
| Cholecalciferol (Vitamin D3) | LC/MS/MS | 1-200 ng/mL | Human EDTA Plasma |
| Cholecalciferol (Vitamin D3); 25-Hydroxy Cholecalciferol (25-Hydroxy Vitamin D3) | LC/MS/MS | 0.5-75 ng/mL ; 1-100 ng/mL | Human EDTA Plasma |
| Cholecalciferol (Vitamin D3); 25-Hydroxy Cholecalciferol (25-Hydroxy Vitamin D3) | LC/MS/MS | 0.5-50 ng/mL ; 1-100 ng/mL | Human EDTA Plasma |
| Cilostazol | LC/MS/MS | 2-1000 ng/mL | Human EDTA Plasma |
| Cilostazol; OPC-13015 | LC/MS/MS | 2-1000 ng/mL; 2-300 ng/mL | Human EDTA Plasma |
| Cilostazol; OPC-13015; OPC-13213 | LC/MS/MS | 2-2000 ng/mL; 2-600 ng/mL; 1-400 ng/mL | Human EDTA Plasma |
| Cinacalcet | LC/MS/MS | 0.1- 50 ng/mL | Human EDTA Plasma |
| Cinitapride | UPLC/MS/MS | 2.5–800 pg/mL | Human EDTA Plasma |
| Cinnarizine | LC/MS/MS | 0.5-100 ng/mL | Human EDTA Plasma |
| Ciprofloxacin | HPLC/FLR | 20-5000 ng/mL | Human EDTA Plasma |
| Citalopram | LC/MS/MS | 0.1-15 ng/mL | Human EDTA Plasma |
| Citrulline | LC/MS/MS | 0.15-10 μg/mL | Human EDTA Plasma |
| Cizolirtine; N-Desmethylcizolirtine | LC/MS/MS | 1-2000 ng/mL | Human Lithium Heparinized Plasma |
| Clarithromycin | LC/MS/MS | 20-4000 ng/mL | Human EDTA Plasma |
| Clarithromycin | LC/MS/MS | 50-4000 ng/mL | Human EDTA Plasma |
| Clavulanic acid | LC/MS | 30-1500 ng/mL | Human EDTA Plasma |
| Clavulanic acid | LC/MS/MS | 10-4000 ng/mL | Human EDTA Plasma |
| Clobazam | LC/MS/MS | 2-500 ng/mL | Human EDTA Plasma |
| Clobazam; N-Desmethylclobazam | LC/MS/MS | 2-750 ng/mL; 0.5-200 ng/mL | Human EDTA Plasma |
| Clonidine | UPLC/MS/MS | 10-2000 pg/mL | Human EDTA Plasma |
| Clopidogrel | LC/MS/MS | 5-2500 pg/mL | Human EDTA Plasma |
| Clopidogrel | LC/MS/MS | 5-5000 pg/mL | Human EDTA Plasma |
| Clopidrogel | LC/MS/MS | 20-10000 pg/mL | Human EDTA Plasma |
| Clopidrogel Carboxylic Acid | LC/MS/MS | 4-4000 ng/mL | Human EDTA Plasma |
| Clopidrogel Carboxylic Acid | LC/MS/MS | 4-3200 ng/mL | Human EDTA Plasma |
| Clozapine | LC/MS/MS | 0.1-50 ng/mL | Human EDTA Plasma |
| Clozapine; N-Desmethyl Clozapine | LC/MS/MS | 2-1000 ng/mL; 1-500 ng/mL | Human EDTA Plasma |
| Codeine | LC/MS/MS | 0.5-100 ng/ mL | Human EDTA Plasma |
| Cortisol | LC/MS/MS | 0.5-100 ng/mL | Human EDTA Plasma |
| Cyclosporin A | LC/MS | 5-1500 ng/mL | Human Whole Blood |
| Cytisine | LC/MS/MS | 5-20000 pg/mL | Human EDTA Plasma |
| Cytisine | LC/MS/MS | 0.1-40 ng/mL | Human EDTA Plasma |
| Dabigatran Unconjugated | LC/MS/MS | 0.5–200 ng/mL | Human EDTA Plasma |
| Dapagliflozin | LC/MS/MS | 0,5-200 ng/mL | Human EDTA Plasma |
| Dasatinib | LC/MS/MS | 1-250 ng/mL | Human EDTA Plasma |
| Dasatinib | LC/MS/MS | 1-500 ng/mL | Human EDTA Plasma |
| Deflazacort metabolite (21-OH-Deflazacort) | LCMS/MS | 1-400 ng/mL | Human EDTA Plasma |
| Descarboethoxy Loratadine; 3-hydroxy Desloratadine | LC/MS/MS | 25-5000 pg/mL; 25-2500 pg/mL | Human EDTA Plasma |
| Desloratadine | LCMS/MS | 25-5000 pg/mL | Human EDTA Plasma |
| Desvenlafaxine (O-Desmethyl Venlafaxine) | LC/MS/MS | 1–500 ng/mL | Human EDTA Plasma |
| Dexamethasone | LC/MS/MS | 0.5-200 ng/mL | Human EDTA Plasma |
| Dexketoprofen | LC/MS/MS | 10-5000 ng/mL | Human EDTA Plasma |
| Dextromethorphan | LC/MS/MS | 5 - 3000 ng/mL | Human EDTA Plasma |
| Diazepam | LC/MS/MS | 1-500 ng/mL | Human EDTA Plasma |
| Diclofenac | LC/MS/MS | 10-2500 ng/mL | Human EDTA Plasma |
| Diclofenac | LC/MS/MS | 10-5000 ng/mL | Human EDTA Plasma |
| Dienogest | LC/MS/MS | 0.5-100 ng/mL | Human EDTA Plasma |
| Dienogest | LC/MS/MS | 1-160 ng/mL | Human EDTA Plasma |
| Digoxin | LC/MS/MS | 50-5000 pg/mL | Human Sodium Heparanized Plasma |
| Diltiazem | LC/MS/MS | 0.5-400 ng/mL | Human Lithium Heparinized Plasma |
| Diltiazem; N-desmethyl Diltiazem; Desacetyl Diltiazem | LC/MS/MS | 0.5-400 ng/mL; 0.5-100 ng/mL; 0.5-50 ng/mL | Human EDTA Plasma |
| Dimenhydrinate (Diphenhydramine) | LC/MS/MS | 0.1-50 ng/mL | Human EDTA Plasma |
| Dimethyl fumarate (refer to Monomethyl fumarate) | |||
| Diosmetin Total; Hesperetin Total | LC/MS/MS | 60-15000 pg/mL; 100-1500 pg/mL | Human EDTA Plasma |
| Diosmetin-3'-O-Glucuronide | LC/MS/MS | 100-60000 pg/mL | Human EDTA Plasma |
| Dipyridamole | LC/MS | 20-4000 ng/mL | Human EDTA Plasma |
| Disulfiram | UPLC/MS/MS | 0.5-100 ng/mL | Human EDTA Plasma |
| Donepezil | LC/MS/MS | 1-100 ng/mL | Human EDTA Plasma |
| Donepezil | HPLC/FLR | 2-50 ng/mL | Human EDTA Plasma |
| Donepezil | LC/MS/MS | 0.1-25 ng/mL | Human EDTA Plasma |
| Donepezil ((+)-Donepezil; (-)-Donepezil) | LC/MS/MS | 100-10000 pg/mL ; 50-5000 pg/mL | Human Sodium Heparinized Plasma |
| Donepezil ((+)-Donepezil; (-)-Donepezil) | LC/MS/MS | 100-20000 pg/mL;50-10000 pg/mL | Human Sodium Heparinized Plasma |
| Doxylamine | LC/MS/MS | 0.5-250 ng/mL | Human EDTA Plasma |
| Doxylamine (R-(-) Doxylamine ; S-(+) Doxylamine) | LC/MS/MS | 0.25-125 ng/mL; 0.25-125 ng/mL | Human EDTA Plasma |
| Dronedarone ; N-Debutyl Dronedarone | LC/MS/MS | 0.5-100 ng/mL; 0.5-100 ng/mL | Human EDTA Plasma |
| Drospirenone | LC/MS/MS | 0.25-100 ng/mL | Human EDTA Plasma |
| Drospirenone | LC/MS/MS | 0.25-100 ng/mL | Human Breast Milk |
| Duloxetine | LC/MS/MS | 0.5-100 ng/mL | Human EDTA Plasma |
| Duloxetine | LC/MS/MS | 0.2-100 ng/mL | Human EDTA Plasma |
| Dutasteride | LC/MS/MS | 50-5000 pg/mL | Human EDTA Plasma |
| Ebastine; Carebastine | LC/MS/MS | 50-20000 pg/mL; 1-400 ng/mL | Human EDTA Plasma |
| Edaravone | LC/MS/MS | 2-7000 ng/mL | Human EDTA Plasma |
| Edaravone | LC/MS/MS | 100-500000 ng/mL | Rabbit EDTA Plasma |
| Edaravone | LC/MS/MS | 2-7000 ng/mL | Human EDTA Plasma |
| Edoxaban | LC/MS/MS | 1-500 ng/mL | Human EDTA Plasma |
| Efavirenz | LC/MS/MS | 20-4000 ng/mL | Human EDTA Plasma |
| Eletriptan; Desmethyl Eletriptan | LC/MS/MS | 500-250000 pg/mL; 50-25000 pg/mL | Human EDTA Plasma |
| Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine) | LC/MS/MS | 5–5000 ng/mL | Human EDTA Plasma |
| Empagliflozin | UPLC/MS/MS | 1 - 500 ng/mL | Human EDTA Plasma |
| Emtricitabine | LC/MS/MS | 20-5000 ng/mL | Human EDTA Plasma |
| Enalapril; Enalaprilat | LC/MS/MS | 0.5-200 ng/mL | Human EDTA Plasma |
| Enalapril; Enalaprilat | LC/MS/MS | 0.25-25 ng/mL | Human EDTA Plasma |
| Entacapone | LC/MS/MS | 10-2000 ng/mL | Human EDTA Plasma |
| Entecavir | LC/MS/MS | 50-10000 pg/mL | Human EDTA Plasma |
| Entecavir | LC/MS/MS | 10-2000 pg/mL | Human EDTA Plasma |
| Eplerenone | LC/MS/MS | 10-2500 ng/mL | Human EDTA Plasma |
| Eplerenone | LC/MS/MS | 50-1500 ng/mL | Human EDTA Plasma |
| Eprosartan | LC/MS/MS | 10-5000 ng/mL | Human EDTA Plasma |
| Erlotinib | LC/MS/MS | 10-2000 ng/mL | Human EDTA Plasma |
| Erlotinib | LC/MS/MS | 10-5000 ng/mL | Human EDTA Plasma |
| Escitalopram | LC/MS/MS | 0.1-15 ng/mL | Human EDTA Plasma |
| Escitalopram | LC/MS/MS | 0.2-30 ng/mL | Human EDTA Plasma |
| Eslicarbazepine | LC/MS/MS | 50–20000 ng/mL | Human EDTA Plasma |
| Esomeprazole | LC/MS/MS | 2-2000 ng/mL | Human EDTA Plasma |
| Esomeprazole | LC/MS/MS | 5-3000 ng/mL | Human EDTA Plasma |
| Esomeprazole | LC/MS/MS | 5-5000 ng/mL | Human EDTA Plasma |
| Estradiol (Unconjugated); Estrone (Unconjugated) | UPLC/MS/MS | 2-100 pg/mL; 5-250 pg/mL | Human EDTA Plasma |
| Estradiol (Unconjugated); Estrone (Unconjugated) | LC/MS/MS | 2.5-100 pg/mL; 5-500 pg/mL | Human EDTA Plasma |
| Estrone (Total) | LC/MS/MS | 50-50000 pg/mL | Human EDTA Plasma |
| Ethinyl Estradiol | UPLC/MS/MS | 1-100 pg/mL | Human EDTA Plasma |
| Ethinyl Estradiol; Gestodene | LC/MS/MS | 2.5-250 pg/mL; 50-25000 pg/mL | Human Serum |
| Etodolac | HPLC-UV | 0.1-20 μg/mL | Human EDTA Plasma |
| Etonogestrel (3-Ketodesogestrel) | LC/MS/MS | 25-5000 pg/mL | Human EDTA Plasma |
| Etoricoxib | LC/MS/MS | 10 -4000 ng/mL | Human EDTA Plasma |
| Exemestane | LC/MS/MS | 0.1-20 ng/mL | Human EDTA Plasma |
| Exemestane | LC/MS/MS | 0.2-40 ng/mL | Human EDTA Plasma |
| Exenatide | UPLC/MS/MS | 30–500 pg/mL | Human EDTA Plasma |
| Ezetimibe (Total) | LC/MS/MS | 0.14-105 ng/mL | Human EDTA Plasma |
| Ezetimibe (Total) | LC/MS/MS | 0.2-150 ng/mL | Human EDTA Plasma |
| Ezetimibe (Unconjugated) | LC/MS/MS | 40-10000 pg/mL | Human EDTA Plasma |
| Famotidine | LC/MS/MS | 0.5-200 ng/mL | Human EDTA Plasma |
| Febuxostat | LC/MS/MS | 50-10000 ng/mL | Human EDTA Plasma |
| Felodipine | LC/MS/MS | 20-10000 pg/mL | Human EDTA Plasma |
| Fenofibric Acid | LC/MS/MS | 50-2500 pg/mL | Human EDTA Plasma |
| Fentanyl | UPLC/MS/MS | 10-2000 pg/mL | Human EDTA Plasma |
| Fentanyl | LC/MS/MS | 25-5000 pg/mL | Human EDTA Plasma |
| Fesoterodine (refer to Tolterodine) | |||
| Finasteride | LC/MS/MS | 0.5-50 ng/mL | Human EDTA Plasma |
| Finasteride | LC/MS/MS | 0.5-50 ng/mL | Human EDTA Plasma |
| Fingolimod; Fingolimod Phosphate | LC/MS/MS | 50-20000 pg/mL ; 50-20000 pg/mL | Human Whole Blood |
| Flecainide | LC/MS/MS | 1-500 ng/mL | Human EDTA Plasma |
| Flecainide | LC/MS/MS | 1-250 ng/mL | Human EDTA Plasma |
| Flecainide | LC/MS/MS | 1-1000 ng/mL | Human EDTA Plasma |
| Flopistrin; Linopristin; Linopristin Metabolite (RPR 208880) | LC/MS/MS | 5-1000 ng/mL; 5-1000 ng/mL; 5-1000 ng/mL | Human Lithium Heparanized Plasma |
| Flopistrin; Linopristin; Linopristin Metabolite (RPR 208880) | LC/MS/MS | 5-1000 ng/mL; 5-1000 ng/mL; 5-1000 ng/mL | Sodium Chloride (0,9%) |
| Fluoxetine | UPLC/MS/MS | 1-80 ng/mL | Human EDTA Plasma |
| Fluoxetine | LC/MS | 1-30 ng/mL | Human EDTA Plasma |
| Fluoxetine; Norfluoxetine | LC/MS/MS | 1-30 ng/mL; 2-60 ng/mL | Human EDTA Plasma |
| Fluoxetine; Norfluoxetine | LC/MS/MS | 0.5-20 ng/mL; 0.5-20 ng/mL | Human EDTA Plasma |
| Flupirtine | LC/MS/MS | 2-1500 ng/mL | Human EDTA Plasma |
| Flupirtine | LC/MS/MS | 2-800 ng/mL | Human EDTA Plasma |
| Fluticasone Propionate | LC/MS/MS | 2-500 pg/mL | Human EDTA Plasma |
| Fluticasone Propionate | UPLC/MS/MS | 2-250 pg/mL | Human EDTA Plasma |
| Fluvastatin | LC-MS/MS | 2-600 ng/mL | Human Sodium Heparinized Plasma |
| Fluvastatin ((+)-3R,5S-Fluvastatin ; (-) -3S, 5R-Fluvastatin) | LC/MS/MS | 0.5-150 ng/mL ; 0.5-150 ng/mL | Human EDTA Plasma |
| Fluvoxamine | LC/MS/MS | 1-400 ng/mL | Human EDTA Plasma |
| Formoterol | LC/MS/MS | 0.2-100 pg/mL | Human NaF/K2C2O4 Plasma |
| Fosinopril | LC/MS/MS | 0.1-10 ng/ mL | Human EDTA Plasma |
| Fosinoprilat | LC/MS/MS | 1-500 ng/mL | Human EDTA Plasma |
| Gabapentin | LC/MS/MS | 50-8000 ng/mL | Human EDTA Plasma |
| Gabapentin | LC/MS | 50-10000 ng/mL | Human EDTA Plasma |
| Galanthamine (with epigalanthamine separation) | LC/MS/MS | 0.5-100 ng/mL | Human EDTA Plasma |
| Gestodene | LC/MS/MS | 50-6250 pg/mL | Human EDTA Plasma |
| Glimepiride | LC/MS/MS | 1-500 ng/mL | Human EDTA Plasma |
| Glimepiride | LC/MS/MS | 1-250 ng/mL | Human EDTA Plasma |
| GLP-1 Active (7-36), GLP-1 Inative (9-36) | MSD | 12.5–2250 pg/mL; 125–22500 pg/mL | Human p800 plasma |
| Glyburide | LC/MS/MS | 2-300 ng/mL | Human EDTA Plasma |
| Glycopyrronium; Indacaterol | UPLC/MS/MS | 1-200 pg/mL; 2-250 pg/mL | Human NaF/K2C2O4 Plasma |
| Goserelin | LC/MS/MS | 0.1-10 ng/mL | Human EDTA Plasma |
| Granisetron | LC/MS/MS | 20-15000 pg/mL | Human EDTA Plasma |
| Haloperidol | LC/MS/MS | 50-6000 pg/mL | Human EDTA Plasma |
| Heparin/Enoxaparin/LMWH (refer to biomarkers Anti-FXa, Anti-FIIa and TFPI) | |||
| Hydrochlorothiazide | LC/MS/MS | 1-150 ng/mL | Human EDTA Plasma |
| Hydrochlorothiazide | LC/MS/MS | 1-300 ng/mL | Human EDTA Plasma |
| Ibandronic acid | LC/MS/MS | 0.5–150 ng/mL | Human EDTA Plasma |
| Ibandronic Acid - Ibandronate | LC/MS/MS | 0.5-100 ng/mL | Human EDTA Plasma |
| Ibuprofen | LC/MS/MS | 150–60000 ng/mL | Human EDTA Plasma |
| Ibuprofen | HPLC/FLR | 0.15-30 ng/mL | Human EDTA Plasma |
| Ibuprofen | LC/MS/MS | 0.15-60 ng/mL | Human EDTA Plasma |
| Ibuprofen | LC/MS/MS | 50-1200 ng/mL | Human EDTAPlasma |
| Ibuprofen (R-(-)-ibuprofen; S-(+)-ibuprofen) | HPLC/FLR | 0.1-20ng/mL; 0.1-20 ng/mL | Human EDTA Plasma |
| Ibuprofen (R-(-)-ibuprofen; S-(+)-ibuprofen) | HPLC/FLR | 0.1-40ng/mL; 0.1-40 ng/mL | Human EDTA Plasma |
| Ibuprofen (R-(-)-ibuprofen; S-(+)-ibuprofen) | LC/MS/MS | 200-40000 ng/mL; 200-40000 ng/mL | Human EDTA Plasma |
| Ibuprofen (R-(-)-ibuprofen; S-(+)-ibuprofen) | LC/MS/MS | 100-20000 ng/mL; 100-20000 ng/mL | Human EDTA Plasma |
| Idebenone (Total) | LC/MS/MS | 40-7500 ng/mL | Human EDTA Plasma |
| Idebenone (Unconjugated) | LC/MS/MS | 40-50000 pg/mL | Human EDTA Plasma |
| Imatinib | LC/MS/MS | 20-4000 ng/mL | Human EDTA Plasma |
| Imatinib; Desmethyl Imatinib | LC/MS/MS | 20-4000 ng/mL; 2-400 ng/mL | Human EDTA Whole Blood |
| Imatinib; Desmethyl Imatinib | LC/MS/MS | 20-4000 ng/mL; 2-400 ng/mL | Human EDTA Plasma |
| Indapamide | LC/MS/MS | 0.5-200 ng/mL | Human EDTA Whole Blood |
| Indapamide | LC/MS/MS | 0.25-125 ng/mL | Human EDTA Whole Blood |
| Irbesartan | LC/MS/MS | 20-6000 ng/mL | Human EDTA Plasma |
| Irbesartan | HPLC/FLR | 20-4000 ng/mL | Human EDTA Plasma |
| Irbesartan | LC/MS/MS | 20-5000 ng/mL | Human EDTA Plasma |
| Irbesartan | LC/MS/MS | 20-8000 ng/mL | Human EDTA Plasma |
| Irinotecan ; SN-38 | LC/MS/MS | 2.5-3500 ng/mL ; 05-100 ng/mL | Human EDTA Plasma |
| Irinotecan ; SN-38 | LC/MS/MS | 2.5-250 ng/mL ; 0.5-50 ng/mL | Human EDTA Plasma |
| Isotretinoin | LC/MS | 2.5-750 ng/mL | Human EDTA Plasma |
| Isotretinoin | LC/MS/MS | 1-300 ng/mL | Human EDTA Plasma |
| Isradipine | LC/MS/MS | 20-5000 pg/mL | Human EDTA Plasma |
| Itraconazole | HPLC/FLR | 2-500 ng/mL | Human EDTA Plasma |
| Ivabradine | LC/MS/MS | 0.1-100 ng/mL | Human EDTA Plasma |
| Ivabradine | LC/MS/MS | 0.1-50 ng/mL | Human EDTA Plasma |
| Ivermectine B1a | LC/MS/MS | 0.4-40 ng/mL | Human EDTA Plasma |
| Ivermectine B1a | LC/MS/MS | 0.4-200 ng/mL | Human EDTA Plasma |
| Ivermectine B1a | LC/MS/MS | 0.4-80 ng/mL | Human EDTA Plasma |
| Ivermectine B1b | LC/MS/MS | 40-5000 pg/mL | Human EDTA Plasma |
| Ivermectine B1b | LC/MS/MS | 40-4000 pg/mL | Human EDTA Plasma |
| Ketamine (refer to S-Ketamine) | |||
| Ketoconazole | LC/MS/MS | 20-1000 ng/mL | Human Sodium Heparinized Plasma |
| Ketoprofen | LC/MS/MS | 10-5000 ng/mL | Human EDTA Plasma |
| L-Ascorbic Acid | LC/MS/MS | 100 - 25000 ng/mL | Human Lithium Heparinized Plasma |
| Lanreotide | UPLC/MS/MS | 0.75 - 100 ng/mL | Rat Plasma |
| Lanreotide | UPLC/MS/MS | 0.1 - 50 ng/mL | Beagle Dog Plasma |
| Lanreotide | UPLC/MS/MS | 0.1-100 ng/mL | Human EDTA Plasma |
| Lansoprazole | LC/MS/MS | 2-2000 ng/mL | Human EDTA Plasma |
| Lapatinib | LC/MS/MS | 0.1-10 μg/mL | Human EDTA Plasma |
| Leflunomide | LC-MS/MS | 20-5000 pg/mL | Human EDTA Plasma |
| Leflunomide metabolite (A77 1726) | LC-MS/MS | 40-16000 ng/mL | Human EDTA Plasma |
| Leflunomide metabolite (A77 1726) | LC/MS/MS | 10-4000 ng/mL | Human EDTA Plasma |
| Lenalidomide | LC/MS/MS | 2-600 ng/mL | Human EDTA Plasma |
| Lenalidomide | LC/MS/MS | 2-600 ng/mL | Human EDTA Plasma |
| Lercanidipine | LC/MS/MS | 25-10000 ng/mL | Human EDTA Plasma |
| Lercanidipine ((-)-R-Lercanidipine; (+)-S-Lercanipidine) | LC-MS/MS | 25-10000 pg/mL; 50-15000 pg/mL | Human EDTA Plasma |
| Letrozole | LC/MS/MS | 0.5-200 ng/mL | Human EDTA Plasma |
| Letrozole | LC/MS/MS | 0.5-100 ng/mL | Human EDTA Plasma |
| Leuprolide | UPLC/MS/MS | 15-4000 pg/mL | Rat EDTA Plasma |
| Leuprolide | UPLC/MS/MS | 50-20000 pg/mL | Rat EDTA Plasma |
| Leuprorelin (refer to Leuprolide) | |||
| Levetiracetam | LC/MS/MS | 0.2-40 μg /mL | Human EDTA Plasma |
| Levetiracetam | LC/MS/MS | 0.1-25 μg/mL | Human EDTA plasma |
| Levodopa | LC/MS/MS | 10-3000 ng/mL | Human EDTA Plasma |
| Levodopa; S-(-)-Carbidopa | LC/MS/MS | 10-7500 ng/mL; 5-1000 ng/mL | Human EDTA Plasma |
| Levofloxacin | HPLC/FLR | 100-15000 ng/mL | Human Serum |
| Levofloxacin | HPLC/FLR | 0.2-100 ng/mL | Human Urine |
| Levonorgestrel | LC/MS/MS | 25-7500 pg/mL | Human EDTA Plasma |
| Levonorgestrel | UPLC/MS/MS | 25-7500 ng/mL | Human EDTA Plasma |
| Levonorgestrel | LC/MS/MS | 250-50000 pg/mL | Human EDTA Plasma |
| Levonorgestrel | LC/MS/MS | 25-5000 pg/mL | Human EDTA Plasma |
| Linagliptin | LC/MS/MS | 50-10000 pg/mL | Human EDTA Plasma |
| Linezolid | LC/MS/MS | 0.1-20 μg/mL | Human EDTA Plasma |
| Linopristin, Linopristin Metabolite (RPR 208880); Flopristin | LC/MS/MS | 5-1000 ng/mL; 5-1000 ng/mL; 5-1000 ng/mL | Human Lithium Heparinized Plasma |
| Linopristin, Linopristin Metabolite (RPR 208880); Flopristin | LC/MS/MS | 5-1000 ng/mL; 5-1000 ng/mL; 5-1000 ng/mL | Sodium Chloride (0,9%) |
| Liraglutide | UPLC/MS/MS | 0.5 - 100 ng/mL | Human EDTA Plasma |
| Lisinopril | LC/MS/MS | 0.5-150 ng/mL | Human EDTA Plasma |
| Loperamide | UPLC/MS/MS | 10-5000 pg/mL | Human EDTA Plasma |
| Loperamide | UPLC/MS/MS | 10 ‑ 5000 pg/mL | Human EDTA Plasma |
| Loratadine; Descarboethoxy Loratadine | LC/MS/MS | 20-20000 pg/mL; 20-20000 pg/mL | Human EDTA Plasma |
| Lorazepam | HPLC/MS/MS | 0.5-50 ng/mL | Human EDTA Plasma |
| Lornoxicam | LC/MS/MS | 2-2000 ng/mL | Human EDTA Plasma |
| Losartan | LC/MS/MS | 2-800 ng/mL | Human EDTA Plasma |
| Losartan; Losartan Carboxy Acid | LC-MS/MS | 1-1600 ng/ mL; 1-1600 ng/ mL | Human EDTA Plasma |
| Losartan; Losartan Carboxy Acid | LC/MS/MS | 2-800 ng/mL; 2-800 ng/mL | Human EDTA Plasma |
| Losartan; Losartan Carboxy Acid | LC-MS/MS | 1-250 ng/mL; 0.5-500 ng/mL | Human Lithium Heparinized Plasma |
| Losartan; Losartan Carboxy Acid | LC-MS/MS | 1-200 ng/mL; 1-400 ng/mL | Human EDTA Plasma |
| Lurasidone | LC/MS/MS | 0.5-200 ng/mL | Human EDTA Plasma |
| Macitentan | LC/MS/MS | 1-400 ng/mL | Human EDTA Plasma |
| Medroxyprogesterone Acetate | LC/MS/MS | 50-10000 pg/mL | Human EDTA Plasma |
| Meloxicam | LC/MS/MS | 10-15000 ng/mL | Human EDTA Plasma |
| Memantine | LC/MS/MS | 100–20000 pg/mL; 200–40000 pg/mL | Human EDTA Plasma |
| Memantine | LC/MS/MS | 0.2-40 ng/mL | Human EDTA Plasma |
| Memantine | LC/MS/MS | 0.1-20 ng/mL | Human EDTA Plasma |
| Mercaptopurine | LC/MS/MS | 1-150 ng/mL | Human EDTA Plasma |
| Mesalamine | LC/MS/MS | 5–2000 ng/mL | Human EDTA Plasma |
| Mesalazine (refer to Mesalamine) | |||
| Mesalazine | LC/MS/MS | 20-12000 ng/mL | Human EDTA Plasma |
| Mesalazine | LC/MS/MS | 1‑500 ng/mL | Human EDTA Plasma |
| Metamizole metabolite (4-methylaminoantipyrine) | LC/MS/MS | 0.5-20 µg/mL | Human EDTA Plasma |
| Metamizole metabolite (4-methylaminoantipyrine) | LC/MS/MS | 0.1–20 µg/mL | Human EDTA Plasma |
| Metformin | LC/MS/MS | 10-5000 ng/mL | Human EDTA Plasma |
| Metformin | LC/MS/MS | 2-2000 ng/mL | Human EDTA Plasma |
| Methocarbamol | LC/MS/MS | 0.5-50 µg/mL | Human EDTA Plasma |
| Methotrexate | LC/MS/MS | 1-500 ng/mL | Human EDTA Plasma |
| Methyl Diethyldithiocarbamate MeDDC (refer to Disulfiram) | |||
| Methylphenidate; Ritalinic Acid | LC/MS/MS | 0.1-20 ng/mL; 2-400 ng/mL | Human EDTA Plasma |
| Methylphenidate; Ritalinic Acid | LC/MS/MS | 0.1-50 ng/mL; 2-100 ng/mL | Human EDTA Plasma |
| Methylprednisolone | LC/MS/MS | 0.25-12.5 ng/mL | Human EDTA Plasma |
| Metoprolol | LC/MS/MS | 0.25-100 ng/mL | Human EDTA Plasma |
| Metoprolol ((+)-R-Metoprolol; (-)-S-Metoprolol) | LC/MS/MS | 0.1-40 ng/mL; 0.1-40 ng/mL | Human EDTA Plasma |
| Midazolam | LC/MS/MS | 0.1-100 ng/mL | Human EDTA Plasma |
| Mifepristone | LC/MS/MS | 5-5000 ng/mL | Human EDTA Plasma |
| Mirabegron | UPLC/MS/MS | 0.1-100 ng/mL | Human EDTA Plasma |
| Mirtazapine | LC/MS/MS | 0.5-150 ng/mL | Human EDTA Plasma |
| Mirtazapine | LC/MS/MS | 0.5-200 ng/mL | Human EDTA Plasma |
| Misoprostol Acid | LC/MS/MS | 10-400 pg/mL | Human EDTA Plasma |
| Misoprostol Acid | LC/MS/MS | 10-2000 pg/mL | Human EDTA Plasma |
| Misoprostol Acid | LC/MS/MS | 10-1000 pg/mL | Human EDTA Plasma |
| Monomethyl fumarate | UPLC/MS/MS | 5 - 3000 ng/mL | Human NaF/K2C2O4 Plasma |
| Montelukast | LC/MS/MS | 2-800 ng/mL | Human EDTA Plasma |
| Montelukast | LC/MS/MS | 2-500 ng/mL | Human EDTA Plasma |
| Montelukast | LC/MS/MS | 2 - 800 ng/mL | Human EDTA Plasma |
| Morphine, Morphine-3-beta-D-glucoronide; Morphine-6-beta-D-glucoronide | LC/MS/MS | 0.25-50 ng/mL; 5-1000 ng/mL; 1-200 ng/mL | Human EDTA Plasma |
| Moxifloxacin | LC/MS/MS | 10-5000 ng/mL | Human Lithium Heparinized Plasma |
| Mycophenolate Mofetil | LC/MS/MS | 20-4000 pg/mL | Human EDTA Plasma |
| Mycophenolic acid | LC/MS/MS | 50-20000 ng/mL | Human EDTA Plasma |
| N-Acetylcysteine | UPLC/MS/MS | 10–2500 ng/mL | Human EDTA Plasma |
| N-Acetylcysteine | LC/MS/MS | 50-7000 ng/mL | Human EDTA Plasma |
| N-Acetylcysteine | LC/MS/MS | 50-3000 ng/mL | Human EDTA Plasma |
| N-mono-desmethyl-sibutramine; N-di-desmethyl-sibutramine | LC/MS/MS | 0.1-5 ng/mL, 0.1-10 ng/mL | Human Sodium Heparinized Plasma |
| Nadolol | LC/MS/MS | 0.5-250 ng/mL | Human EDTA Plasma |
| Naloxone (Unconjugated) | LC/MS/MS | 1-600 ng/mL | Human EDTA Plasma |
| Naproxen | LC/MS/MS | 200–100000 ng/mL | Human EDTA Plasma |
| Naratriptan | LC/MS/MS | 50-25000 pg/mL | Human EDTA Plasma |
| Nateglinide | LC/MS/MS | 50-20000 ng/mL | Human EDTA Plasma |
| Nateglinide | LC/MS/MS | 50-10000 ng/mL | Human EDTA Plasma |
| Nebivolol | LC/MS/MS | 20-2500 pg/mL | Human EDTA Plasma |
| Nebivolol | LC/MS/MS | 10-7500 pg/mL | Human EDTA Plasma |
| Nebivolol | UPLC/MS/MS | 10 ‑ 5000 pg/mL | Human EDTA Plasma |
| Nevirapine | LC/MS | 30-3000 ng/mL | Human EDTA Plasma |
| Nicorandil | LC/MS/MS | 0.5-200 ng/mL | Human EDTA Plasma |
| Nicorandil | LC/MS/MS | 0.5-400 ng/mL | Human EDTA Plasma |
| Nicotinamide Adenine Dinucleotide; Nicotinamide Mononucleotide (NAD NMN) | LC/MS/MS | 600-100000 ng/mL; 30-5000 ng/mL | Sprague Dawley rat whole blood with sodium citrate 3.2% and Sprague Dawley rat plasma with sodium citrate 3.2% |
| Nicotine | UPLC/MS/MS | 0.4-40 ng/mL | Human EDTA Plasma |
| Nifedipine | LC/MS/MS | 0.2-100 ng/mL | Human EDTA Plasma |
| Nilotinib | UPLC/MS/MS | 1–750 ng/mL | Human EDTA Plasma |
| Nilotinib | LC/MS/MS | 1-750 ng/mL | Human EDTA Plasma |
| Nitrofurantoin | LC/MS/MS | 1-1000 ng/mL | Human EDTA Plasma |
| NP 031112 | LC/MS/MS | 2.5-1000 pg/mL | Human EDTA Plasma |
| NP 04113 | LC/MS/MS | 2.5-1000 pg/mL | Human EDTA Plasma |
| Octopamine | LC/MS/MS | 1-30 µg/mL | Human Lithium Heparinized Plasma |
| Octreotide | UPLC/MS/MS | 100-75000 pg/mL | Rat Plasma |
| Octreotide | UPLC/MS/MS | 25 – 25000 pg/mL | Rat Plasma |
| Olanzapine | LC/MS/MS | 50–10000 pg/mL | Human EDTA Plasma |
| Olanzapine | LC/MS/MS | 0.2-25 ng/mL | Human EDTA Plasma |
| Olanzapine | LC/MS/MS | 0.2-50 ng/mL | Human EDTA Plasma |
| Olanzapine | LC/MS/MS | 40-10000 pg/mL | Human EDTA Plasma |
| Olmesartan | LC/MS/MS | 3-1500 ng/mL | Human EDTA Plasma |
| Olmesartan | LC/MS/MS | 2.5-2500 ng/mL | Human EDTA Plasma |
| Olodaterol | UPLC/MS/MS | 0.2-50 pg/mL | Human EDTA Plasma |
| Omeprazole | LC/MS/MS | 5-1000 ng/mL | Human EDTA Plasma |
| Omeprazole | LC/MS/MS | 5-2000 ng/mL | Dog Plasma |
| Ondasetron | LC/MS/MS | 0.25-100 ng/mL | Human EDTA Plasma |
| Ondasetron | LC/MS | 100-1000 ng/mL | Human Lithium Heparinized Plasma |
| Opipramol | LC/MS/MS | 0.1-40 μg/mL | Human EDTA Plasma |
| Orlistat | LC/MS/MS | 10-4000 pg/mL | Human EDTA Plasma |
| Orlistat M1 | LC/MS/MS | 100-40000 pg/mL | Human EDTA Plasma |
| Oxcarbazepine | LC/MS/MS | 5-2500 ng/mL | Human EDTA Plasma |
| Oxcarbazepine; 10-Hydroxycarbamazepine | LC/MS/MS | 5-2500 ng/mL; 30-15000 ng/mL | Human EDTA Plasma |
| Oxycodone | LC/MS/MS | 100–20000 pg/mL | Human EDTA Plasma |
| Oxycodone | LC/MS/MS | 0.1-20 ng/mL | Human EDTA Plasma |
| Oxycodone | LC/MS/MS | 0.5-150 ng/mL | Human EDTA Plasma |
| Paliperidone ((-) Paliperidone; (+) Paliperidone) | LC/MS/MS | 50-10000 pg/mL; 50-10000 pg/mL | Human EDTA Plasma |
| Paliperidone (9-OH Risperidone) | LC/MS/MS | 100–50000 pg/mL | Human EDTA Plasma |
| Paliperidone (9-OH Risperidone) | LC/MS/MS | 100-15000 pg/mL | Human EDTA Plasma |
| Paliperidone (9-OH Risperidone) | LC/MS/MS | 100-15000 pg/mL | Beagle Dog EDTA Plasma |
| Pantoprazole | LC/UV | 10-2000 ng/mL | Human EDTA Plasma |
| Pantoprazole | LC/MS/MS | 20-2000 ng/mL | Human EDTA Plasma |
| Paracetamol/Acetaminophen | LC/MS/MS | 0.15-20 µg/mL | Human EDTA Plasma |
| Paracetamol/Acetaminophen | LC/MS/MS | 0.15-15 μg/mL | Human EDTA Plasma |
| Paricalcitol | LC/MS/MS | 5-250 pg/mL | Human EDTA Plasma |
| Paricalcitol | LC/MS/MS | 10-1000 pg/mL | Human EDTA Plasma |
| Paroxetine | UPLC/MS/MS | 100-50000 pg/mL | Human EDTA Plasma |
| Pentoxyfiline; Metabolite I; Metabolite V | LC/MS/MS | 1-500 ng/mL; 2-1000 ng/mL; 3-1500 ng/mL | Human EDTA Plasma |
| Perindopril | LC/MS/MS | 400-200000 pg/mL | Human EDTA Plasma |
| Perindopril; Perindoprilat | LC/MS/MS | 0.4-160 ng/mL ; 0.1-40 ng/mL | Human EDTA Plasma |
| Perindopril; Perindoprilat | LC/MS/MS | 200-80000 pg/mL ; 50-20000 pg/mL | Human EDTA Plasma |
| Phenylephrine | LC/MS/MS | 10-2000 pg/mL | Human EDTA Plasma |
| Pioglitazone | LC/MS/MS | 2-750 ng/mL | Human EDTA Plasma |
| Pioglitazone, Hydroxypioglitazone; Ketopioglitazone | LC/MS/MS | 10-2000 ng/mL ; 10-1000 ng/mL ; 2-400 ng/mL | Human EDTA Plasma |
| Pioglitazone; Hydropioglitazone | LC/MS/MS | 10-2000 ng/mL; 10-1000 ng/mL | Human EDTA Plasma |
| Pioglitazone; Hydropioglitazone | LC/MS/MS | 10-3000 ng/mL; 10-1500 ng/mL | Human EDTA Plasma |
| Piracetam | LC/MS/MS | 0.5-50 µg/mL | Human EDTA Plasma |
| Pirlindole | LC/MS/MS | 0.5-500 ng/mL | Human EDTA Plasma |
| Pirlindole (R-(-)Pirlindole; S-(+)Pirlindole) | LC/MS/MS | 0.25-200 ng/mL; 0.25-200 ng/mL | Rat EDTA Plasma |
| Pitavastatin | LC/MS/MS | 0.5–200 ng/mL | Human EDTA Plasma |
| Pomalidomide | LC/MS/MS | 0.5-200 ng/mL | Human EDTA Plasma |
| Pramipexole | LC/MS/MS | 10-1000 pg/mL | Human EDTA Plasma |
| Pramipexole | LC/MS/MS | 50-5000 pg/mL | Human EDTA Plasma |
| Pramipexole | LC/MS/MS | 40-4000 pg/mL | Human EDTA Plasma |
| Prasugrel metabolite R-95913 | LC/MS/MS | 0.5-100 ng/mL | Human EDTA Plasma |
| Pravastatin | LC/MS/MS | 0.4-200 ng/mL | Human EDTA Plasma |
| Pravastatin; 3-α-Hydroxy Pravastatin | LC/MS/MS | 0.25-100 ng/mL; 0.25-100 ng/mL | Human EDTA Plasma |
| Prednisolone | LC/MS/MS | 1-100 ng/mL | Rat Sodium Heparinized Plasma |
| Prednisone; Prednisolone | LC/MS/MS | 1-50 ng/mL; 5-250 ng/ mL | Human EDTA Plasma |
| Pregabalin | LC/MS/MS | 5-2500 ng/mL | Human EDTA Plasma |
| Pregabalin | LC/MS/MS | 30-15000 ng/mL | Human EDTA Plasma |
| Progesterone | LC/MS/MS | 50-30000 pg/mL | Human EDTA Plasma |
| Progesterone | LC/MS/MS | 100-30000 pg/mL | Human EDTA Plasma |
| Progesterone | UPLC/MS/MS | 100 ‑ 30000 pg/mL | Female Human EDTA Plasma |
| Propofol | LC/MS | 5-3000 ng/mL | Human EDTA Whole Blood |
| Pseudoephedrine | LC/MS/MS | 1-250 ng/mL | Human EDTA Plasma |
| Pseudoephedrine (S,S(+)-Pseudoephedrine) | LC/MS/MS | 1-1000 ng/mL | Human EDTA Plasma |
| Pseudoephedrine (S,S(+)-Pseudoephedrine) | LC/MS/MS | 1-300 ng/mL | Human EDTA Plasma |
| Pyridoxine (Vitamin B6); Pyridoxal; Pyridoxal 5-phosphate | LC/MS/MS | 0.2-100 ng/mL; 1-250 ng/mL; 0.5-150 ng/mL | Human EDTA Plasma |
| Quetiapine | LC/MS/MS | 0.5–200 ng/mL | Human EDTA Plasma |
| Quetiapine | LC/MS/MS | 0.5 - 200 ng/mL | Rat plasma EDTA |
| Quetiapine | LC/MS/MS | 1-1000 ng/mL | Human EDTA Plasma |
| Quetiapine | LC/MS/MS | 0.5-125 ng/mL | Human EDTA Plasma |
| Quetiapine | LC/MS/MS | 2-1500 ng/mL | Human EDTA Plasma |
| R-95913 (Prasugrel metabolite) | LC/MS/MS | 0.5-100 ng/mL | Human EDTA Plasma |
| Bicalutamide (R-(-)Bicalutamide) | LC/MS/MS | 4-2000 ng/mL | Human EDTA Plasma |
| R(+)-Baclofen; S(-)-Baclofen | LC/MS/MS | 0.5-200 ng/mL | Human EDTA Plasma |
| Rabeprazole | LC/MS/MS | 2-1000 ng/mL | Human EDTA Plasma |
| Racecadotril (refer to Thiorphan) | |||
| Raloxifene | LC/MS/MS | 10-1000 pg/mL | Human EDTA Plasma |
| Raloxifene-4-glucuronide; Raloxifene-6-glucuronide | LC/MS/MS | 0.6-150 ng/mL; 0.3-75 ng/mL | Human EDTA Plasma |
| Ramipril | LC/MS/MS | 0.1-30 ng/mL | Human EDTA Plasma |
| Ramipril | LC/MS/MS | 0.2-80 ng/mL | Human EDTA Plasma |
| Ramipril; Furosemide | UPLC/MS/MS | 200-80000 pg/mL; 2-800 ng/mL | Human EDTA Plasma |
| Ramipril; Ramiprilat | UPLC/MS/MS | 200 – 80000 pg/mL | Human EDTA Plasma |
| Ramipril; Ramiprilat | LC/MS/MS | 0.2-50 ng/mL ; 0.2-50 ng/mL | Human EDTA Plasma |
| Ramipril; Ramiprilat | UPLC/MS/MS | 0.2-80 ng/mL; 0.2-80 ng/mL | Human EDTA Plasma |
| Ranitidine | LC/MS/MS | 4-1600 ng/mL | Human EDTA Plasma |
| Rasagiline | LC/MS/MS | 10-10000 pg/mL | Human EDTA Plasma |
| Repaglinide | LC/MS/MS | 0.1-50 ng/mL | Human EDTA Plasma |
| Rhein (Diacerein metabolite) | LC/MS/MS | 50-5000 ng/mL | Human EDTA Plasma |
| Riluzole | LC/MS/MS | 1-1000 ng/mL | Human EDTA Plasma |
| Risedronic Acid | LC/MS/MS | 0.2-16 ng/mL | Human EDTA Plasma |
| Risedronic Acid | LC/MS/MS | 0.2-50 ng/mL | Human EDTA Plasma |
| Risedronic Acid | LC/MS/MS | 0.2-50 ng/mL | Human Sodium Heparinized Plasma |
| Risperidone; 9-OH-Risperidone | LC/MS/MS | 100–20000 pg/mL; 100–20000 pg/mL | Human EDTA Plasma |
| Risperidone; 9-OH-Risperidone | LC/MS/MS | 0.25-125 ng/mL ; 1-250 ng/mL | Beagle Dog EDTA Plasma |
| Risperidone; 9-OH-Risperidone | LC/MS/MS | 0.1-30 ng/mL ; 0.1-15 ng/mL | Human EDTA Plasma |
| Rivaroxaban | LC/MS/MS | 0.5-200 ng/mL | Human EDTA Plasma |
| Rivaroxaban | LC/MS/MS | 0.5-500 ng/mL | Human EDTA Plasma |
| Rivastigmine | LC/MS/MS | 0.2-40 ng/mL | Human EDTA Plasma |
| Rivastigmine | LC/MS/MS | 40-4000 pg/mL | Human EDTA Plasma |
| Rivastigmine | LC/MS/MS | 0.2-20 ng/mL | Human EDTA Plasma |
| Rivastigmine | LC/MS/MS | 0.1-10 ng/mL | Human EDTA Plasma |
| Rivastigmine; NAP 226-90 | LC/MS/MS | 50–15000 pg/mL ; 25–7500 pg/mL | Human EDTA Plasma |
| Rivastigmine; NAP 226-90 | LC/MS/MS | 400–30000 pg/mL ; 400–30000 pg/mL | Human EDTA Plasma |
| Rizatriptan | LC/MS/MS | 0.1-40 ng/mL | Human EDTA Plasma |
| Ropinirole | LC/MS/MS | 100-2000 pg/mL | Human EDTA Plasma |
| Ropinirole | LC/MS/MS | 5-1000 pg/mL | Human EDTA Plasma |
| Rosiglitazone | LC/MS/MS | 2-900 ng/mL | Human EDTA Plasma |
| Rosiglitazone | LC/MS/MS | 1-400 ng/mL | Human EDTA Plasma |
| Rosuvastatin | LC/MS/MS | 50-25000 pg/mL | Human EDTA Plasma |
| Rosuvastatin | LC/MS/MS | 20-8000 pg/mL | Human EDTA Plasma |
| Rosuvastatin | LC/MS/MS | 80-4000 pg/mL | Human EDTA Plasma |
| Rupatadine | LC/MS/MS | 25-5000 pg/mL | Human EDTA Plasma |
| S-Ketamine ; S-Norketamine | UPLC/MS/MS | 0.25-250 ng/mL; 0.25-250 ng/mL | Human EDTA Plasma |
| Sacubitril; Valsartan | LC/MS/MS | 5-3500 ng/mL; 10-7000 ng/mL | Human NaF/K2C2O4 Plasma |
| Salmeterol | UPLC/MS/MS | 2-250 pg/mL | Human EDTA Plasma |
| Salmeterol | UPLC/MS/MS | 1-300 pg/mL | Human EDTA Plasma |
| Semaglutide | UPLC/MS/MS | 0.5 - 50 ng/mL | Human EDTA Plasma |
| Sibutramine (R(+)-Sibutramine ; S(-)-Sibutramine) | LC/MS/MS | 15-12500 pg/mL ; 50-12500 pg/mL | Human Sodium Heparinized Plasma |
| Sibutramine (R(+)-Sibutramine ; S(-)-Sibutramine) | LC/MS/MS | 15-7500 pg/mL ; 15-3000 pg/mL | Human Sodium Heparinized Plasma |
| Sildenafil | LC/MS/MS | 2–1000 ng/mL | Human EDTA Plasma |
| Sildenafil | LC/MS/MS | 2-500 ng/mL | Human EDTA Plasma |
| Sildenafil; desmethyl Sildenafil | LC/MS/MS | 2-500 ng/mL; 1-250 ng/mL | Human EDTA Plasma |
| Silodosin | LC/MS/MS | 0.2 - 100 ng/mL | Human EDTA Plasma |
| Silodosin | UPLC/MS/MS | 0.2-100 ng/mL | Human EDTA Plasma |
| Silodosin Glucuronide | UPLC/MS/MS | 0.5-200 ng/mL | Human EDTA Plasma |
| Simvastatin | LC/MS/MS | 50-5000 pg/mL | Human EDTA Plasma |
| Simvastatin | LC/MS/MS | 0.1-20 ng/mL | Human EDTA Plasma |
| Simvastatin | LC/MS/MS | 0.2-40 ng/mL | Human EDTA Plasma |
| Simvastatin; b-Hydroxy Acid Simvastatin | LC/MS/MS | 0.2-40 ng/mL; 0.2-10 ng/mL | Human EDTA Plasma |
| Simvastatin; b-Hydroxy Acid Simvastatin | LC/MS/MS | 0.1-20 ng/mL ; 0.1-5 ng/mL | Human EDTA Plasma |
| Sitagliptin | LC/MS/MS | 1-500 ng/mL | Human EDTA Plasma |
| Solifenacin | LC/MS/MS | 0.1-30 ng/mL | Human EDTA Plasma |
| Solifenacin | LC/MS/MS | 0.1-15 ng/mL | Human EDTA Plasma |
| Solifenacin | LC/MS/MS | 0.1-20 ng/mL | Human EDTA Plasma |
| Sorafenib | UPLC/MS/MS | 5-5000 ng/mL | Human EDTA Plasma |
| Spironolactone; Canrenone | UPLC/MS/MS | 0.5-100 ng/mL; 1-200 ng/mL | Human EDTA Plasma |
| Sumatriptan | LC/MS/MS | 1-100 ng/mL | Human EDTA Plasma |
| Sunitinib | LC/MS/MS | 0.25-100 ng/mL | Human EDTA Plasma |
| Tacrolimus | LC/MS/MS | 0.2 – 50 ng/mL | Rat EDTA blood |
| Tacrolimus | LC/MS/MS | 0.25-20 ng/mL | Human EDTA Whole Blood |
| Tacrolimus | LC/MS/MS | 0.25-50 ng/mL | Human EDTA Whole Blood |
| Tacrolimus | LC/MS/MS | 50-50000 pg/mL | Human EDTA Whole Blood |
| Tadalafil | LC/MS/MS | 1-200 ng/mL | Human EDTA Plasma |
| Tadalafil | LC/MS/MS | 1-500 ng/mL | Human EDTA Plasma |
| Tadalafil | LC/MS/MS | 5-1000 ng/mL | Human EDTA Plasma |
| Tamoxifen Isomers E and Z | UPLC/MS/MS | 1.25-250 ng/g | Rat muscle |
| Tamoxifen; N-Desmethyl Tamoxifen | LC/MS/MS | 0.5-50 ng/mL; 0.5-25 ng/mL | Human EDTA Plasma. |
| Tamsulosin | LC/MS/MS | 100-25000 pg/mL | Human EDTA Plasma |
| Tamsulosin | LC/MS/MS | 0.15-30 ng/mL | Human EDTA Plasma |
| Telmisartan | LC/MS/MS | 1-1500 ng/mL | Human EDTA Plasma |
| Telmisartan | LC/MS/MS | 0.5-200 ng/mL | Human EDTA Plasma |
| Temozolomide | UPLC/MS/MS | 100–25000 ng/mL | Human EDTA Plasma |
| Temozolomide | LC/MS/MS | 0.1-25 μg/mL | Human EDTA Plasma |
| Tenofovir | LC/MS/MS | 5-750 ng/mL | Human Serum |
| Terbinafine | LC/MS/MS | 10-5000 ng/mL | Diluted Digested Human Nail Clippings |
| Teriflunomide (refer to Leflunomide Metabolite) | |||
| Testosterone | LC/MS/MS | 0.1-20 ng/mL | Human Serum |
| Tetrahydrocannabinol; 11-Hydroxy-Tetrahydrocannabinol; Cannabidiol | LC/MS/MS | 0.2-20 ng/mL; 0.2-20 ng/mL; 0.1-10 ng/mL | Human EDTA Plasma. |
| TFPI | ELISA | 31.3-2000 pg/mL | Human Citrate Plasma |
| THC; OH-THC; CBD | LC/MS/MS | 0.2-20 ng/mL; 0.2-20 ng/mL; 0.1-10 ng/mL | Human EDTA Plasma |
| Thiorphan (Racecadotril) | LC/MS/MS | 1-250 ng/mL | Human EDTA Plasma |
| Tiagabine | LC/MS/MS | 0.5-1000 ng/mL | Human EDTA Plasma |
| Tianeptine; Tianeptine MC5 Metabolite | LC/MS/MS | 5-500 ng/mL; 2.5-250 ng/mL | Human Sodium Heparinized Plasma |
| Tibolone | LC/MS/MS | 100-5000 pg/mL | Human EDTA Plasma. |
| Ticagrelor | LC/MS/MS | 2–1000 ng/mL | Human EDTA Plasma |
| Ticagrelor; Deshydroxyethoxy Ticagrelor | UPLC/MS/MS | 2-1000 ng/mL; 0.5-250 ng/mL | Human EDTA Plasma |
| Tiotropium | LC/MS/MS | 0.5-100 pg/mL | Human EDTA Plasma |
| Tiotropium | UPLC/MS/MS | 0.2-50 pg/mL | Human EDTA Plasma |
| Tolterodine; 5-hydroxymethyl Tolterodine | LC/MS/MS | 20-4000 pg/mL; 20-4000 pg/mL | Human EDTA Plasma. |
| Tolterodine; 5-hydroxymethyl Tolterodine | LC/MS/MS | 50-10000 pg/mL; 50-10000 pg/mL | Human EDTA Plasma. |
| Topiramate | LC/MS/MS | 10-1000 ng/mL | Human EDTA Plasma |
| Topiramate | LC/MS/MS | 20-4000 ng/mL | Human EDTA Plasma |
| Torasemide | HPLC-UV | 10-3000 ng/mL | Human Plasma |
| Torasemide | LC/MS/MS | 10-5000 ng/mL | Human EDTA Plasma |
| Torsemide | LC/MS/MS | 50-20000 ng/mL | Human EDTA Plasma |
| Tramadol; O-desmethyltramadol | LC/MS/MS | 1-500 ng/mL; 0.5-150 ng/mL | Human EDTA Plasma |
| Trandolapril; Trandolaprilat | LC/MS/MS | 50-5000 pg/mL; 200-10000 pg/mL | Human EDTA Plasma |
| Trazodone | LC/MS/MS | 10-2400 ng/mL | Human EDTA Plasma |
| Tretinoin | LC/MS/MS | 1-150 ng/mL | Human EDTA Plasma |
| Triamcinolone Acetonide | LC-MS/MS | 100-8000 pg/mL | Human EDTA Plasma |
| Trimetazidine | LC-MS/MS | 1-100 ng/mL | Human EDTA Plasma |
| Ursodiol, Glycoursodeoxycholic Acid; Tauroursodeoxycholic Acid | UPLC/MS/MS | 10–10000 ng/mL, 10–10000 ng/mL; 0.5–250 ng/mL | Human EDTA Plasma |
| Ursodiol, Glycoursodeoxycholic Acid; Tauroursodeoxycholic Acid | LC/MS/MS | 6-6000 ng/mL, 12-6000 ng/mL; 0.5-250 ng/mL | Human EDTA Plasma |
| Valacyclovir | LC/MS/MS | 1-400 ng/mL | Human EDTA Plasma |
| Valganciclovir ; Ganciclovir | UPLC/MS/MS | 2-700 ng/mL; 50-10000 ng/mL | Human EDTA Plasma |
| Valproic Acid | LC/MS/MS | 0.5-75 µg/mL | Human EDTA Plasma |
| Valsartan | LC-MS/MS | 20-5000 ng/mL | Human EDTA Plasma |
| Valsartan | LC/MS/MS | 20-10000 ng/mL | Human EDTA Plasma |
| Valsartan | LC/MS/MS | 30-15000 ng/mL | Human EDTA Plasma |
| Valsartan | LC/MS/MS | 20-7500 ng/mL | Human EDTA Plasma |
| Vardenafil | LC/MS/MS | 0.1-20 ng/mL | Human EDTA Plasma |
| Venlafaxine; O-desmethylvenlafaxine | LC/MS/MS | 0.5-75 ng/mL; 1-200 ng/mL | Human EDTA Plasma |
| Venlafaxine; O-desmethylvenlafaxine | LC/MS/MS | 1-150 ng/mL; 2-200 ng/mL | Human EDTA Plasma |
| Venlafaxine; O-desmethylvenlafaxine | LC/MS/MS | 5-200 ng/mL; 5-400 ng/mL | Human EDTA Plasma |
| Venlafaxine; O-desmethylvenlafaxine | LC-MS/MS | 1-200 ng/mL; 3-300 ng/mL | Human EDTA Plasma |
| Verapamil ; Norverapamil | LC/MS/MS | 1-500 ng/mL; 1-500 ng/mL | Human EDTA Plasma |
| Vildagliptin | LC/MS/MS | 1-500 ng/mL | Human EDTA Plasma |
| Voriconazole | LC/MS/MS | 5-2000 ng/mL | Human EDTA Plasma |
| Vortioxetine | UPLC/MS/MS | 25-15000 pg/mL | Human EDTA Plasma |
| Vortioxetine | UPLC/MS/MS | 25-5000 pg/mL | Human EDTA Plasma |
| Warfarin | HPLC/FLR | 20-1500 ng/mL | Human EDTA Plasma |
| Warfarin (R-(+) Warfarin, S-(-)-Warfarin) | LC/MS/MS | 50-7500 pg/mL; 50-3000 pg/mL | Human Sodium Heparinized Plasma |
| Warfarin (R-(+) Warfarin, S-(-)-Warfarin) | LC/MS/MS | 50-12500 pg/mL; 50-12500 pg/mL | Human Sodium Heparinized Plasma |
| Warfarin (R-(+) Warfarin, S-(-)-Warfarin) | LC/MS/MS | 10-2000 ng/mL | Human EDTA Plasma |
| Ziprasidone | LC/MS | 0.5-100 ng/mL | Human EDTA Plasma |
| Zoledronic Acid | LC/MS/MS | 5-5000 ng/mL | Human Urine |
| Zolmitriptan; N-desmethylzolmitriptan | LC/MS/MS | 100-20000 pg/mL; 50-10000 pg/mL | Human EDTA Plasma |
| Zolpidem | LC/MS/MS | 0.25-62.5 ng/mL | Human EDTA Plasma |
| Zonisamide | LC/MS/MS | 10-3000 ng/mL | Human Serum |
| Zonisamide | LC/MS/MS | 10-2000 ng/mL | Human Serum |